As of May 31, 2025, Arcus Biosciences Inc (RCUS) reports a ROA (Return on Assets) of -24.61%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Arcus Biosciences Inc's ROA (Return on Assets)
Over recent years, Arcus Biosciences Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -24.61% |
| 2023-12-31 | -28.04% |
| 2022-12-31 | -19.85% |
| 2021-12-31 | 3.32% |
| 2020-12-31 | -15.91% |
This fluctuation highlights how Arcus Biosciences Inc manages its efficiency in using assets to generate earnings over time.
Comparing Arcus Biosciences Inc's ROA (Return on Assets) to Peers
To better understand Arcus Biosciences Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Arcus Biosciences Inc (RCUS) | -24.61% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| Amgen Inc (AMGN) | 4.45% |
| Abbvie Inc (ABBV) | 3.17% |
| Gilead Sciences Inc (GILD) | 0.81% |
| Seres Therapeutics Inc (MCRB) | 0.10% |
Compared to its competitors, Arcus Biosciences Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.